Home >> Healthcare >> Food & Beverage >>

Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 157 | Code: MRS - 35117

Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Squamous Non-Small Cell Lung Cancer - Pipeline Review, H2 2015’, provides an overview of the Squamous Non-Small Cell Lung Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Squamous Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Squamous Non-Small Cell Lung Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Squamous Non-Small Cell Lung Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Squamous Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Squamous Non-Small Cell Lung Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Squamous Non-Small Cell Lung Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Squamous Non-Small Cell Lung Cancer - Overview 10
Pipeline Products for Squamous Non-Small Cell Lung Cancer - Comparative Analysis 11
Squamous Non-Small Cell Lung Cancer - Therapeutics under Development by Companies 12
Squamous Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 14
Squamous Non-Small Cell Lung Cancer - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Squamous Non-Small Cell Lung Cancer - Products under Development by Companies 18
Squamous Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes 20
Squamous Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 21
AbbVie Inc. 21
Advenchen Laboratories, LLC 22
Ascenta Therapeutics, Inc. 23
AstraZeneca Plc 24
AVEO Pharmaceuticals, Inc. 25
Bayer AG 26
BIND Therapeutics, Inc. 27
Boehringer Ingelheim GmbH 28
Bristol-Myers Squibb Company 29
Eli Lilly and Company 30
F. Hoffmann-La Roche Ltd. 31
Five Prime Therapeutics, Inc. 32
Genentech, Inc. 33
Incyte Corporation 34
Johnson & Johnson 35
MacroGenics, Inc. 36
Novartis AG 37
Oncogenex Pharmaceuticals, Inc. 38
PsiOxus Therapeutics Limited 39
Vertex Pharmaceuticals Incorporated 40
Squamous Non-Small Cell Lung Cancer - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
abemaciclib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ABT-414 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
apatorsen - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AT-406 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
atezolizumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
AV-203 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
AZD-2014 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
AZD-8186 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
BAY-1163877 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
BMS-906024 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
buparlisib hydrochloride - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
docetaxel - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
enadenotucirev - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
enoblituzumab - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
FP-1039 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
iMDK - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
INCB-54828 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
ipilimumab - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
JNJ-42756493 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
lucitanib - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
LY-3023414 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
necitumumab - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
nintedanib - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
prexasertib - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Small Molecule to Inhibit TWIST1 for Non-Small Cell Lung Cancer - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
taselisib - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
veliparib - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
VX-970 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Squamous Non-Small Cell Lung Cancer - Recent Pipeline Updates 111
Squamous Non-Small Cell Lung Cancer - Dormant Projects 148
Squamous Non-Small Cell Lung Cancer - Discontinued Products 149
Squamous Non-Small Cell Lung Cancer - Product Development Milestones 150
Featured News & Press Releases 150
Aug 24, 2015: Five Prime Therapeutics Announces Oral Presentation of Initial Data From Ongoing Phase 1b Trial of FP-1039/GSK3052230 in Squamous Non Small Cell Lung Cancer and Mesothelioma at World Conference on Lung Cancer 150
Jul 09, 2015: Lilly Statement on FDA Advisory Committee Review of Necitumumab 150
Jun 10, 2015: Survival benefit with 'fully human' EGFR antibody necitumumab in squamous NSCLC 151
May 27, 2015: FDA Advisory Committee To Discuss On Lilly’s BLA For necitumumab injection In July 2015 152
May 20, 2015: OncoGenex To Present Phase II Study Data On Apatorsen At ASCO 2015 Annual Meeting 152
Feb 24, 2015: OncoGenex and Sarah Cannon Announce Completion of Patient Enrollment in the Spruce Clinical Trial Evaluating Apatorsen in Combination with Carboplatin and Pemetrexed in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer 153
Oct 23, 2014: Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer 153
Jul 01, 2014: OncoGenex Announces Cedar Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment 154
May 14, 2014: Clovis Oncology Announces Clinical Data Of Lucitanib to Be Presented at 2014 ASCO Annual Meeting 155
Aug 13, 2013: Eli Lilly and Company's Phase III study of necitumumab meets primary endpoint 155
Appendix 156
Methodology 156
Coverage 156
Secondary Research 156
Primary Research 156
Expert Panel Validation 156
Contact Us 156
Disclaimer 157

List of Tables
Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H2 2015 10
Number of Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Development by Companies, H2 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2015 20
Squamous Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc., H2 2015 21
Squamous Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2015 22
Squamous Non-Small Cell Lung Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015 23
Squamous Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2015 24
Squamous Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 25
Squamous Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H2 2015 26
Squamous Non-Small Cell Lung Cancer - Pipeline by BIND Therapeutics, Inc., H2 2015 27
Squamous Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 28
Squamous Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015 29
Squamous Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2015 30
Squamous Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 31
Squamous Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics, Inc., H2 2015 32
Squamous Non-Small Cell Lung Cancer - Pipeline by Genentech, Inc., H2 2015 33
Squamous Non-Small Cell Lung Cancer - Pipeline by Incyte Corporation, H2 2015 34
Squamous Non-Small Cell Lung Cancer - Pipeline by Johnson & Johnson, H2 2015 35
Squamous Non-Small Cell Lung Cancer - Pipeline by MacroGenics, Inc., H2 2015 36
Squamous Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H2 2015 37
Squamous Non-Small Cell Lung Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2015 38
Squamous Non-Small Cell Lung Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2015 39
Squamous Non-Small Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 40
Assessment by Monotherapy Products, H2 2015 41
Number of Products by Stage and Target, H2 2015 43
Number of Products by Stage and Mechanism of Action, H2 2015 46
Number of Products by Stage and Route of Administration, H2 2015 49
Number of Products by Stage and Molecule Type, H2 2015 51
Squamous Non-Small Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H2 2015 111
Squamous Non-Small Cell Lung Cancer - Dormant Projects, H2 2015 148
Squamous Non-Small Cell Lung Cancer - Discontinued Products, H2 2015 149

List of Figures
Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H2 2015 10
Number of Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Assessment by Monotherapy Products, H2 2015 41
Number of Products by Top 10 Targets, H2 2015 42
Number of Products by Stage and Top 10 Targets, H2 2015 42
Number of Products by Top 10 Mechanism of Actions, H2 2015 45
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 45
Number of Products by Top 10 Routes of Administration, H2 2015 48
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 48
Number of Products by Top 10 Molecule Types, H2 2015 50
Number of Products by Stage and Top 10 Molecule Types, H2 2015 50

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

Single User | $(USD)2000 View Pricing